SavedAdd your journal

Journals / European Journal of General Medicine / 2010 / Cilt: 7 Sayı: 4

ARIPIPRAZOLE IN DELUSIONAL DISORDER, A CASE REPORT

Halide Duvar
Cem Sengul
Hasan Herken
Pages
1–1
Publication Date
2010-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗

Özet

-

🔖

Cite This Article

Duvar, H., Sengul, C., Herken, H. (2010). ARIPIPRAZOLE IN DELUSIONAL DISORDER, A CASE REPORT. European Journal of General Medicine, Cilt: 7 Sayı: 4, 1–1. https://ajindex.com/articles/987770

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Abdel-Hamid M, Brüne M. Neuropsychological aspects of delusional disorder. Curr Psychiatry Rep 2008;10:229-34.
  2. Manschreck TC, Khan NL: Recent advances in the treatment of delusional disorder. Can J Psychiatry 2006;51:114–9.
  3. Myers WC, Ruiz R: Aripiprazole and psychotherapy for delusional disorder, erotomanic type. J Am Acad Child Adolesc Psychiatry 2004;43:1069-70.
  4. Rocha FL, Hara C. Aripiprazole in delusional parasitosis: Case report. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:784-6.
  5. Freudenmann RW. A case of delusional parasitosis in severe heart failure. Olanzapine within the framework of a multimodal therapy. Nervenarzt 2003;74: 591–5.
  6. Chae BJ, Kang BJ. Quetiapine for hypersexuality and delusional jealousy after stroke. J Clin Psychopharmacol 2006;26:331–2.
  7. Kitamura H. A case of somatic delusional disorder that responded to treatment with risperidone. Psychiatry Clin Neurosci. 1997;51:337.
  8. Monkul SE, Akdede BB. Aripiprazole: A new atypical antipsyhotic drug. Bulletin of Clinical Psychopharmacology 2005;15:198-203.
  9. Soygür H. Pharmacokinetic and pharmacodynamic characteristics of aripiprazole. Bulletin of Clinical Psychopharmacology 2008:18(Suppl. 1):1-6.
  10. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20:612-27.
  11. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004;18:375-83.
  12. Alptekin K. New generation antipsychotics in the treatment of schizophrenia: dopamine stabilizing agents and aripiprazole. Bulletin of Clinical Psychopharmacology 2008:18(Suppl. 1):21-6.
  13. Potkin SG, Saha AR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681–90.
  14. Chrzanowski WK, Marcus RN. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;189:259-66.
  15. Dimopoulos N, Mitsonis C, Psarra V. Delusional disorder, somatic type treated with aripiprazole mirtazapine combination. J Psychopharmacol 2008;22:812-4.